Related Experiment Videos
Vesicant extravasation: myths and realities
1Cancer Center, Fairfax Hospital, VA.
Oncology Nursing Forum
|January 1, 1995
Summary
This review addresses common misconceptions about antineoplastic vesicant extravasation, aiming to improve patient outcomes and reduce liability for oncology nurses. Understanding and debunking these myths is crucial for effective prevention and management strategies.
Area of Science:
- Oncology Nursing
- Patient Safety
- Pharmacology
Background:
- Antineoplastic vesicant extravasation poses significant risks to cancer patients' quality of life.
- Extravasation injuries are challenging to study, leading to underreporting and knowledge gaps.
- Misconceptions among oncology nurses complicate the management of these critical events.
Purpose of the Study:
- To comprehensively review literature on antineoplastic vesicant extravasation.
- To address and debunk common misconceptions held by oncology nurses regarding extravasation.
- To improve the prevention and management of vesicant extravasation injuries.
Main Methods:
- Review of national guidelines.
- Analysis of published articles in professional specialty journals and proceedings.
- Inclusion of authors' clinical experiences with vesicant agents.
Main Results:
- Extravasation can cause severe morbidity and impact patient quality of life.
- The incidence of extravasation from vascular access devices is unknown.
- Empirical data often forms the basis for management strategies due to study limitations.
Conclusions:
- Debunking 10 myths about vesicant extravasation is key to translating guidelines into practice.
- Oncology nurses are vital in assessing the efficacy of prevention and management guidelines.
- Nurses must maintain current knowledge and adhere to standards of practice for vesicant administration.